论文部分内容阅读
目前国内外临床应用的肿瘤光化学诊治剂的共同缺点是对肿瘤的选择性摄入率不够高,且均为未知结构的卟啉混合物,这些缺点影响了它们的临床使用价值和进一步成为商品药物的可能性。Winkelman等报道TPPS对大鼠Walker癌-256的肿瘤/正常组
The common shortcomings of the currently used tumor photochemical diagnostic and therapeutic agents for clinical application at home and abroad are that the selective uptake rate to tumors is not high enough and they are all porphyrin mixtures of unknown structure. These disadvantages affect their clinical use value and further become commercial drugs. possibility. Winkelman et al. Reported TPPS on Ratker Cancer-256 Tumor/Normal Group